Merck plans trial of sac-TMT combo with Keytruda in lung cancer
Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy Keytruda. The company plans to conduct a trial testing its experimental antibody-drug conjugate sac-TMT in combination ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.